Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences, Inc.

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience, specifically in developing therapies for Alzheimer's disease. Its mission includes detecting and treating Alzheimer's disease.

NASDAQ:SAVA

Cassava Sciences, Inc.

Last Close

29.58

25/09 14:39

Market Cap

535.41M

Beta: −0.13

Volume Today

473.99K

Avg: 703.16K

PE Ratio

−10.57

PFCF: −11.93